Exhibit 3

JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Rigel Pharmaceuticals, Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
 
IN WITNESS WHEREOF, each of the undersigned hereby executes this Agreement as of this 11th day of January, 2008.
 
       
 
D. E. Shaw Composite Portfolios, L.L.C.     
  By: D. E. Shaw & Co., L.L.C., as
    managing member
 
 		  
 		    
 
    
By: 
 /s/ Rochelle Elias
   
Rochelle Elias
Chief Compliance Officer
 
       
 
D. E. Shaw Valence Portfolios, L.L.C.
  By: D. E. Shaw & Co., L.P., as
    managing member
 
 		  
 		    
 
    
By: 
 /s/ Rochelle Elias
   
Rochelle Elias
Chief Compliance Officer
 
     
  D. E. Shaw & Co., L.L.C.
 
 		  
 		  
 
  By:    /s/ Rochelle Elias
 
Rochelle Elias
Chief Compliance Officer
 
     
  D. E. Shaw & Co., L.P.
 
 		  
 		  
 
  By:    /s/ Rochelle Elias
 
Rochelle Elias
Chief Compliance Officer
 
     
  David E. Shaw
 
 		  
 		  
 
  By:    /s/ Rochelle Elias
 
Rochelle Elias
Attorney-in-Fact for David E. Shaw